ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen

Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel...

Descripción completa

Detalles Bibliográficos
Autores principales: M. Sieuwerts, Anieta, A. Inda, Márcia, Smid, Marcel, van Ooijen, Henk, van de Stolpe, Anja, Martens, John W. M., Verhaegh, Wim F. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226576/
https://www.ncbi.nlm.nih.gov/pubmed/32230714
http://dx.doi.org/10.3390/cancers12040802

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226576/
https://www.ncbi.nlm.nih.gov/pubmed/32230714
http://dx.doi.org/10.3390/cancers12040802

Ejemplares similares